Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer

von King, Carly J., Woodward, Josha, Schwartzman, Jacob, Coleman, Daniel J., Lisac, Robert, Wang, Nicholas J., Van Hook, Kathryn, Gao, Lina, Urrutia, Joshua, Dane, Mark A., Heiser, Laura M., Alumkal, Joshi J.
Veröffentlicht in Oncotarget (2017)

Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer

von Coleman, Daniel J., Gao, Lina, Schwartzman, Jacob, Korkola, James E., Sampson, David, Derrick, Daniel S., Urrutia, Joshua, Balter, Ariel, Burchard, Julja, King, Carly J., Chiotti, Kami E., Heiser, Laura M., Alumkal, Joshi J.
Veröffentlicht in Sci Rep (2019)

BET Bromodomain Inhibition Blocks the Function of a Critical AR-Independent Master Regulator Network in Lethal Prostate Cancer

von Coleman, Daniel J., Gao, Lina, King, Carly J., Schwartzman, Jacob, Urrutia, Joshua, Sehrawat, Archana, Tayou, Junior, Balter, Ariel, Burchard, Julja, Chiotti, Kami E., Derrick, Daniel S., Sun, Duanchen, Xia, Zheng, Heiser, Laura M., Alumkal, Joshi J.
Veröffentlicht in Oncogene (2019)

Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4

von Coleman, Daniel J., Sampson, David A., Sehrawat, Archana, Kumaraswamy, Anbarasu, Sun, Duanchen, Wang, Yuzhuo, Schwartzman, Jacob, Urrutia, Joshua, Lee, Ahn R., Coleman, Ilsa M., Nelson, Peter S., Dong, Xuesen, Morrissey, Colm, Corey, Eva, Xia, Zheng, Yates, Joel A., Alumkal, Joshi J.
Veröffentlicht in Neoplasia (2020)

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor

von Coleman, Daniel J., Van Hook, Kathryn, King, Carly J., Schwartzman, Jacob, Lisac, Robert, Urrutia, Joshua, Sehrawat, Archana, Woodward, Josha, Wang, Nicholas J., Gulati, Roman, Thomas, George V., Beer, Tomasz M., Gleave, Martin, Korkola, James E., Gao, Lina, Heiser, Laura M., Alumkal, Joshi J.
Veröffentlicht in Oncotarget (2016)

Copy Number Loss of 17q22 is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer

von Guan, Xiangnan, Sun, Duanchen, Lu, Eric, Urrutia, Joshua A., Reiter, Robert Evan, Rettig, Matthew, Evans, Christopher P., Lara, Primo, Gleave, Martin, Beer, Tomasz M., Thomas, George V., Huang, Jiaoti, Aggarwal, Rahul R., Quigley, David A., Foye, Adam, Chen, William S., Youngren, Jack, Weinstein, Alana S., Stuart, Joshua M., Feng, Felix Y., Small, Eric J., Xia, Zheng, Alumkal, Joshi J.
Veröffentlicht in Clin Cancer Res (2020)

LSD1 activates a lethal prostate cancer gene network independently of its demethylase function

von Sehrawat, Archana, Gao, Lina, Wang, Yuliang, Bankhead, Armand, McWeeney, Shannon K., King, Carly J., Schwartzman, Jacob, Urrutia, Joshua, Bisson, William H., Coleman, Daniel J., Joshi, Sunil K., Kim, Dae-Hwan, Sampson, David A., Weinmann, Sheila, Kallakury, Bhaskar V. S., Berry, Deborah L., Haque, Reina, Van Den Eeden, Stephen K., Sharma, Sunil, Bearss, Jared, Beer, Tomasz M., Thomas, George V., Heiser, Laura M., Alumkal, Joshi J.
Veröffentlicht in Proc Natl Acad Sci U S A (2018)

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance

von Alumkal, Joshi J., Sun, Duanchen, Lu, Eric, Beer, Tomasz M., Thomas, George V., Latour, Emile, Aggarwal, Rahul, Cetnar, Jeremy, Ryan, Charles J., Tabatabaei, Shaadi, Bailey, Shawna, Turina, Claire B., Quigley, David A., Guan, Xiangnan, Foye, Adam, Youngren, Jack F., Urrutia, Joshua, Huang, Jiaoti, Weinstein, Alana S., Friedl, Verena, Rettig, Matthew, Reiter, Robert E., Spratt, Daniel E., Gleave, Martin, Evans, Christopher P., Stuart, Joshua M., Chen, Yiyi, Feng, Felix Y., Small, Eric J., Witte, Owen N., Xia, Zheng
Veröffentlicht in Proc Natl Acad Sci U S A (2020)